Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis ; volume:22 ; number:1 ; day:7 ; month:6 ; year:2022 ; pages:1-9 ; date:12.2022
BMC neurology ; 22, Heft 1 (7.6.2022), 1-9, 12.2022
- Creator
-
Fox, Robert J.
Mehta, Rina
Pham, Timothy
Park, Julie
Wilson, Kathleen
Bonafede, Machaon
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-022-02738-7
- URN
-
urn:nbn:de:101:1-2022080419272414672521
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fox, Robert J.
- Mehta, Rina
- Pham, Timothy
- Park, Julie
- Wilson, Kathleen
- Bonafede, Machaon
- SpringerLink (Online service)
Other Objects (12)
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Claims for disease-modifying therapy by Alberta non-insured health benefits clients
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Current Disease-Modifying Therapies in Multiple Sclerosis
Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study
Disease-modifying treatments in Alzheimer’s disease
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Claims for disease-modifying therapy by Alberta non-insured health benefits clients
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Current Disease-Modifying Therapies in Multiple Sclerosis
Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study
Disease-modifying treatments in Alzheimer’s disease
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
Claims for disease-modifying therapy by Alberta non-insured health benefits clients
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
Current Disease-Modifying Therapies in Multiple Sclerosis
Early high-efficacy disease-modifying therapy in multiple sclerosis: a 4-year real-world study
Disease-modifying treatments in Alzheimer’s disease
Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis